CDKN2A and mucinous neoplasm: A mutation screening of RAS/RAF pathway in mucinous ovarian neoplasia showed that p16 loss and RAS/RAF pathway alterations are highly recurrent events, occurring early during mucinous tumor development: the frequency of concurrence of these events was observed in 40% of benign cystadenomas and 6% of borderline tumors [112].